STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Cellectis (NASDAQ:CLLS) has released its monthly share capital and voting rights report as of June 30, 2025. The company reported a total of 100,325,229 shares in its capital structure and 89,428,630 voting rights.

This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+1.27%
1 alert
+1.27% News Effect

On the day this news was published, CLLS gained 1.27%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PARIS, July 04, 2025 (GLOBE NEWSWIRE) --

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting rights
06/30/2025100,325,22989,428,630

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment


FAQ

What is the current number of shares outstanding for Cellectis (CLLS) as of June 2025?

As of June 30, 2025, Cellectis has 100,325,229 total shares outstanding in its capital structure.

How many voting rights does Cellectis (CLLS) have as of June 2025?

Cellectis reported 89,428,630 total voting rights as of June 30, 2025.

Where is Cellectis (CLLS) stock listed?

Cellectis is listed on Euronext Growth with the ISIN code FR0010425595.

Who should investors contact for Cellectis (CLLS) investor relations?

Investors can contact Arthur Stril, Chief Financial Officer & Chief Business Officer, at investors@cellectis.com.
Cellectis

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Latest SEC Filings

CLLS Stock Data

409.33M
72.33M
3.85%
18.77%
0.21%
Biotechnology
Healthcare
Link
France
Paris